Alexia Savignoni

4.0k total citations
108 papers, 2.4k citations indexed

About

Alexia Savignoni is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Alexia Savignoni has authored 108 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 45 papers in Cancer Research and 21 papers in Pathology and Forensic Medicine. Recurrent topics in Alexia Savignoni's work include Breast Cancer Treatment Studies (37 papers), Ocular Oncology and Treatments (18 papers) and Breast Lesions and Carcinomas (17 papers). Alexia Savignoni is often cited by papers focused on Breast Cancer Treatment Studies (37 papers), Ocular Oncology and Treatments (18 papers) and Breast Lesions and Carcinomas (17 papers). Alexia Savignoni collaborates with scholars based in France, United States and Canada. Alexia Savignoni's co-authors include Bernard Asselain, Alain Fourquet, Brigitte Sigal‐Zafrani, Youlia Kirova, Xavier Sastre‐Garau, Marc A. Bollet, Geneviève Almouzni, Jean‐Yves Pierga, Rémy Salmon and R. Dendale and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Blood.

In The Last Decade

Alexia Savignoni

104 papers receiving 2.4k citations

Peers

Countries citing papers authored by Alexia Savignoni

Since Specialization

Citations

This map shows the geographic impact of Alexia Savignoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexia Savignoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexia Savignoni more than expected).

Fields of papers citing papers by Alexia Savignoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexia Savignoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexia Savignoni. The network helps show where Alexia Savignoni may publish in the future.

Co-authorship network of co-authors of Alexia Savignoni

This figure shows the co-authorship network connecting the top 25 collaborators of Alexia Savignoni. A scholar is included among the top collaborators of Alexia Savignoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexia Savignoni. Alexia Savignoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of second ipsilateral breast tumor event: An advocacy for a randomized trial 2024 ·Cancer/Radiothérapie ·Jean‐Michel Hannoun‐Lévi, Alexia Savignoni, (unknown), Caroline Malhaire, (unknown), Anne Brédart, Pierre Loap, Youlia Kirova	3
2	319TiP NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC) 2024 ·Annals of Oncology ·Estelle Bastien, (unknown), (unknown), (unknown), Delphine Loirat, Marie‐Paule Sablin, Anne Vincent‐Salomon, (unknown), (unknown), Caroline Malhaire, Alexia Savignoni, Emanuela Romano	1
3	Selective Ophthalmic Artery Chemotherapy with Melphalan in the Management of Unilateral Retinoblastoma: A Prospective Study 2021 ·Ophthalmology Retina ·Livia Lumbroso‐Le Rouic, Raphaël Blanc, (unknown), Alexia Savignoni, Hervé J. Brisse, N. Pierrat, Christine Lévy‐Gabriel, Alexandre Matet, François Doz, Isabelle Aerts, Nathalie Cassoux	5
4	Helping Patients Communicate With Oncologists When Cancer Treatment Resistance Occurs to Develop, Test, and Implement a Patient Communication Aid: Sequential Collaborative Mixed Methods Study 2021 ·JMIR Research Protocols ·Anne Brédart, (unknown), (unknown), É. Seigneur, Leanne de Koning, (unknown), Alexia Savignoni, Paul Cottu, Jean‐Yves Pierga, Sophie Piperno‐Neumann, Manuel Rodrigues, Carole Bouleuc, Sylvie Dolbeault	2
5	Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI 2019 ·Cancers ·Pascale Mariani, Sylvain Dureau, Alexia Savignoni, Livia Lumbroso‐Le Rouic, Christine Lévy‐Gabriel, Sophie Piperno‐Neumann, Manuel Rodrigues, Laurence Desjardins, Nathalie Cassoux, Vincent Servois	20
6	Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database 2019 ·Breast Cancer Research and Treatment ·(unknown), (unknown), J-Y Pierga, Étienne Brain, Roman Rouzier, Alexia Savignoni, (unknown), Véronique Dièras, (unknown), Coraline Dubot, Matthieu Carton, F. Lerebours	7
7	Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation 2019 ·PLoS ONE ·(unknown), Marie‐Laure Tanguy, Paul Cottu, Brigitte De La Lande, P. Bontemps, C. Lemanski, Pierre Baumann, Alexia Savignoni, Christelle Lévy, Karine Peignaux, A. Reynaud-Bougnoux, (unknown), Youlia Kirova	6
8	Correlation between RB1germline mutations and second primary malignancies in hereditary retinoblastoma patients treated with external beam radiotherapy 2018 ·European Journal of Medical Genetics ·(unknown), Gaël A. Millot, Constance Wells, Hervé J. Brisse, Marick Laé, Alexia Savignoni, Laurence Desjardins, R. Dendale, François Doz, Isabelle Aerts, Irène Jiménez, Nathalie Cassoux, (unknown), (unknown), Claude Houdayer	23
9	Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003 2016 ·Cancer/Radiothérapie ·Jean‐Marc Cosset, T Flam, Lisa Belin, Nicolas Thiounn, N. Pierrat, D. Pontvert, (unknown), Alexia Savignoni, L. Chauveinc	29
10	Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy 2015 ·Eye ·Livia Lumbroso‐Le Rouic, Isabelle Aerts, David Hajage, Christine Lévy‐Gabriel, Alexia Savignoni, (unknown), Nathalie Cassoux, (unknown), Marc Estève, François Doz, Laurence Desjardins	20
11	Matching methods to create paired survival data based on an exposure occurring over time: a simulation study with application to breast cancer 2014 ·BMC Medical Research Methodology ·Alexia Savignoni, (unknown), Pascale Tubert‐Bitter, Yann De Rycke	6
12	Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome 2012 ·Familial Cancer ·Pascale This, Anne de la Rochefordière, Alexia Savignoni, (unknown), A. Tardivon, Fabienne Thibault, S. Alran, (unknown), Alfred Fitoussi, Benoît Couturaud, Sylvie Dolbeault, Rémy Salmon, Brigitte Sigal‐Zafrani, Bernard Asselain, Dominique Stoppa‐Lyonnet	13
13	Clinical significance and prognostic value of chromatin assembly factor‐1 overexpression in human solid tumours 2010 ·Histopathology ·Sophie E. Polo, Stamatios Theocharis, Laure Grandin, Laëtitia Gambotti, Guillemette Antoni, Alexia Savignoni, Bernard Asselain, Efstratios Patsouris, Geneviève Almouzni	43
14	Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer 2010 ·The EMBO Journal ·Armelle Corpet, Leanne de Koning, Joern Toedling, Alexia Savignoni, Frédérique Berger, Charlène Lemaître, Roderick J. O’Sullivan, Jan Karlseder, Emmanuel Barillot, Bernard Asselain, Xavier Sastre‐Garau, Geneviève Almouzni	131
15	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients 2010 ·Breast Cancer Research and Treatment ·Jean‐Yves Pierga, Suzette Delaloge, Marc Espié, Étienne Brain, Brigitte Sigal‐Zafrani, Marie‐Christine Mathieu, Philippe Bertheau, (unknown), M. Spielmann, Alexia Savignoni, M. Marty	85
16	Management of Operable Invasive Breast Cancer in Women Over the Age of 70: Long-Term Results of a Large-Scale Single-Institution Experience 2010 ·Annals of Surgical Oncology ·F. Laki, Youlia Kirova, Alexia Savignoni, François Campana, (unknown), Marc Estève, Brigitte Sigal‐Zafrani, Thierry Dorval, Bernard Asselain, Rémy Salmon	11
17	Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison 2007 ·Pediatric Radiology ·Hervé J. Brisse, (unknown), Isabelle Aerts, Xavier Sastre‐Garau, Alexia Savignoni, Livia Lumbroso‐Le Rouic, Laurence Desjardins, François Doz, Bernard Asselain, (unknown), S. Neuenschwander	64
18	Phyllodes tumors of the breast segregate in two groups according to genetic criteria 2007 ·Modern Pathology ·Marick Laé, Anne Vincent‐Salomon, Alexia Savignoni, (unknown), Paul Fréneaux, Brigitte Sigal‐Zafrani, Alain Aurias, Xavier Sastre‐Garau, Jérôme Couturier	59
19	Chromatin Assembly Factor-1, a Marker of Clinical Value to Distinguish Quiescent from Proliferating Cells 2004 ·Cancer Research ·Sophie E. Polo, Stamatios Theocharis, Jerzy Klijanienko, Alexia Savignoni, Bernard Asselain, Philippe Vielh, Geneviève Almouzni	75
20	Medullary breast carcinoma: Prognostic implications of p53 expression 2003 ·The International Journal of Biological Markers ·R. Dendale, Anne Vincent‐Salomon, (unknown), Alexia Savignoni, F. Campana, Jacques Médioni, J.R. Vilcoq, (unknown), Thierry Soussi, Bernard Asselain, Patricia de Crémoux, Alain Fourquet	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact